Luca Benatti - 23 Oct 2023 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Role
Director
Signature
/s/ Brendan Hannah, Attorney-in-Fact for Luca Benatti
Issuer symbol
QNCX
Transactions as of
23 Oct 2023
Net transactions value
$0
Form type
4
Filing time
24 Oct 2023, 19:46:54 UTC
Previous filing
25 May 2023
Next filing
13 Nov 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QNCX Employee Stock Option (right to buy) Award $0 +54,000 $0.000000 54,000 23 Oct 2023 Common Stock 54,000 $0.9900 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of October 23, 2023, subject to the Reporting Person's continued service as a member of the Board of Directors of the Issuer as of each such vesting date.